Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells-Reference-Cited by-同舟云学术

Crosstown Traffic: Lymphodepleting Chemotherapy Drives CAR T Cells

Published:2021-02 Issue:2 Volume:39 Page:138-140
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Davies David M.,Maher John

Funder

Breast Cancer Now

British Lung Foundation

Wellcome Trust

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference10 articles.

1. Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer;Arai;J. Immunother. Cancer,2020

2. Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy - what are we doing; where are we going?;Bechman;Expert Opin. Biol. Ther.,2020

3. Engineering CAR-T cells for next-generation cancer therapy;Hong;Cancer Cell,2020

4. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice;Lesterhuis;J. Clin. Invest.,2011

5. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses;Liu;Br. J. Cancer,2010

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances;Journal of Controlled Release;2024-04

2. Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle;Frontiers in Immunology;2023-12-22

3. Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma;International Journal of General Medicine;2023-09

4. CAR T Cell Therapy: Remedies of Current Challenges in Design, Injection, Infiltration and Working;Drug Design, Development and Therapy;2023-06

5. New cell sources for CAR-based immunotherapy;Biomarker Research;2023-05-06